-positive 0 9 0 9 O
and/or 10 16 10 16 O
PR 17 19 17 19 O
- 19 20 19 20 O
positive 20 28 20 28 O
/ 28 29 28 29 O
HER2- 29 34 29 34 B-cancer
disease 35 42 35 42 O
and 43 46 43 46 O
received 47 55 47 55 O
no 56 58 56 58 O
more 59 63 59 63 O
than 64 68 64 68 O
1 69 70 69 70 B-upper_bound
prior 71 76 71 76 B-treatment
non 77 80 77 80 I-treatment
- 80 81 80 81 I-treatment
hormonally 81 91 81 91 I-treatment
- 91 92 91 92 I-treatment
directed 92 100 92 100 I-treatment
or 101 103 101 103 I-treatment
cytotoxic 104 113 104 113 I-treatment
therapy 114 121 114 121 I-treatment
in 122 124 122 124 I-treatment
the 125 128 125 128 I-treatment
MBC 129 132 129 132 I-treatment
setting 133 140 133 140 I-treatment

Combination 0 11 141 152 O
Arm 12 15 153 156 O
: 15 16 156 157 O
HER2 17 21 158 162 B-cancer
- 21 22 162 163 I-cancer
positive 22 30 163 171 I-cancer
disease 31 38 172 179 I-cancer
and 39 42 180 183 O
received 43 51 184 192 O
at 52 54 193 195 O
least 55 60 196 201 O
2 61 62 202 203 B-lower_bound
prior 63 68 204 209 I-lower_bound
cytotoxic 69 78 210 219 O
regimens 79 87 220 228 O
in 88 90 229 231 O
the 91 94 232 235 O
incurable 95 104 236 245 O
, 104 105 245 246 O
unresectable 106 118 247 259 O
, 118 119 259 260 O
LA 120 122 261 263 O
/ 122 123 263 264 O
MBC 123 126 264 267 O
setting 127 134 268 275 O
( 135 136 276 277 O
not 136 139 277 280 O
enrolling 140 149 281 290 O
new 150 153 291 294 O
patients 154 162 295 303 O
) 162 163 303 304 O

Combination 0 11 305 316 O
Arm 12 15 317 320 O
: 15 16 320 321 O
hypersensitivity 17 33 322 338 O
to 34 36 339 341 O
trastuzumab 37 48 342 353 B-allergy_name

Eastern 0 7 354 361 B-clinical_variable
Cooperative 8 19 362 373 I-clinical_variable
Oncology 20 28 374 382 I-clinical_variable
Group 29 34 383 388 I-clinical_variable
performance 35 46 389 400 I-clinical_variable
status 47 53 401 407 I-clinical_variable
0 54 55 408 409 B-lower_bound
or 56 58 410 412 O
1 59 60 413 414 B-upper_bound

Malignant 0 9 415 424 B-cancer
CNS 10 13 425 428 I-cancer
disease 14 21 429 436 I-cancer
that 22 26 437 441 O
has 27 30 442 445 O
not 31 34 446 449 O
been 35 39 450 454 O
definitively 40 52 455 467 O
treated 53 60 468 475 O

Pathologically 0 14 476 490 O
confirmed 15 24 491 500 O
diagnosis 25 34 501 510 O
of 35 37 511 513 O
breast 38 44 514 520 B-cancer
cancer 45 51 521 527 I-cancer
with 52 56 528 532 O
radiographic 57 69 533 545 O
evidence 70 78 546 554 O
of 79 81 555 557 O
incurable 82 91 558 567 O
, 91 92 567 568 O
unresectable 93 105 569 581 O
, 105 106 581 582 O
locally 107 114 583 590 O
advanced 115 123 591 599 O
or 124 126 600 602 O
metastatic 127 137 603 613 B-cancer
disease 138 145 614 621 I-cancer
( 146 147 622 623 O
LA 147 149 623 625 O
/ 149 150 625 626 O
MBC 150 153 626 629 O
) 153 154 629 630 O

Pre 0 3 631 634 B-clinical_variable
- 3 4 634 635 I-clinical_variable
existing 4 12 635 643 I-clinical_variable
neuropathy 13 23 644 654 I-clinical_variable
Grade 24 29 655 660 B-lower_bound
2 30 31 661 662 I-lower_bound
or 32 34 663 665 O
higher 35 41 666 672 O

Prior 0 5 673 678 O
treatment 6 15 679 688 O
with 16 20 689 693 O
SGN 21 24 694 697 B-treatment
- 24 25 697 698 I-treatment
LIV1A 25 30 698 703 I-treatment

Triple 0 6 704 710 B-cancer
- 6 7 710 711 I-cancer
negative 7 15 711 719 I-cancer
disease 16 23 720 727 I-cancer
( 24 25 728 729 O
ER 25 27 729 731 O
/ 27 28 731 732 O
PR 28 30 732 734 O
/ 30 31 734 735 O
HER2 31 35 735 739 O
- 35 36 739 740 O
negative 36 44 740 748 O
) 44 45 748 749 O
and 46 49 750 753 O
received 50 58 754 762 O
at 59 61 763 765 O
least 62 67 766 771 O
2 68 69 772 773 O
prior 70 75 774 779 B-treatment
cytotoxic 76 85 780 789 I-treatment
regimens 86 94 790 798 I-treatment
in 95 97 799 801 O
the 98 101 802 805 O
incurable 102 111 806 815 O
, 111 112 815 816 O
unresectable 113 125 817 829 O
, 125 126 829 830 O
LA 127 129 831 833 O
/ 129 130 833 834 O
MBC 130 133 834 837 O
setting 134 141 838 845 O
; 141 142 845 846 O
or 143 145 847 849 O
ER 146 148 850 852 O
- 148 149 852 853 O
positive 149 157 853 861 O
and/or 158 164 862 868 O
PR 165 167 869 871 O
- 167 168 871 872 O
positive 168 176 872 880 O
/ 176 177 880 881 O
HER2 177 181 881 885 O
- 181 182 885 886 O
negative 182 190 886 894 O
disease 191 198 895 902 O
and 199 202 903 906 O
received 203 211 907 915 O
at 212 214 916 918 O
least 215 220 919 924 O
2 221 222 925 926 O
prior 223 228 927 932 O
cytotoxic 229 238 933 942 O
regimens 239 247 943 951 O
in 248 250 952 954 O
the 251 254 955 958 O
incurable 255 264 959 968 O
, 264 265 968 969 O
unresectable 266 278 970 982 O
, 278 279 982 983 O
LA 280 282 984 986 O
/ 282 283 986 987 O
MBC 283 286 987 990 O
setting 287 294 991 998 O
and 295 298 999 1002 O
are 299 302 1003 1006 O
no 303 305 1007 1009 O
longer 306 312 1010 1016 O
a 313 314 1017 1018 O
candidate 315 324 1019 1028 O
for 325 328 1029 1032 O
hormonal 329 337 1033 1041 B-treatment
therapy 338 345 1042 1049 I-treatment
( 346 347 1050 1051 O
not 347 350 1051 1054 O
enrolling 351 360 1055 1064 O
new 361 364 1065 1068 O
patients 365 373 1069 1077 O
) 373 374 1077 1078 O

Triple 0 6 1079 1085 B-cancer
- 6 7 1085 1086 I-cancer
negative 7 15 1086 1094 I-cancer
disease 16 23 1095 1102 I-cancer
and 24 27 1103 1106 O
received 28 36 1107 1115 O
1 37 38 1116 1117 O
prior 39 44 1118 1123 O
non 45 48 1124 1127 O
- 48 49 1127 1128 O
hormonally 49 59 1128 1138 O
- 59 60 1138 1139 O
directed 60 68 1139 1147 O
or 69 71 1148 1150 O
cytotoxic 72 81 1151 1160 B-treatment
therapy 82 89 1161 1168 I-treatment
in 90 92 1169 1171 O
the 93 96 1172 1175 O
MBC 97 100 1176 1179 O
setting 101 108 1180 1187 O

Triple 0 6 1188 1194 B-cancer
- 6 7 1194 1195 I-cancer
negative 7 15 1195 1203 I-cancer
disease 16 23 1204 1211 O
and 24 27 1212 1215 O
received 28 36 1216 1224 O
2 37 38 1225 1226 B-lower_bound
- 38 39 1226 1227 O
4 39 40 1227 1228 B-upper_bound
prior 41 46 1229 1234 I-upper_bound
non 47 50 1235 1238 B-treatment
- 50 51 1238 1239 I-treatment
hormonally 51 61 1239 1249 I-treatment
- 61 62 1249 1250 I-treatment
directed 62 70 1250 1258 I-treatment
therapies 71 80 1259 1268 I-treatment
in 81 83 1269 1271 O
the 84 87 1272 1275 O
MBC 88 91 1276 1279 B-clinical_variable
setting 92 99 1280 1287 O
( 100 101 1288 1289 O
not 101 104 1289 1292 O
enrolling 105 114 1293 1302 O
new 115 118 1303 1306 O
patients 119 127 1307 1315 O
) 127 128 1315 1316 O

prior 0 5 1317 1322 O
treatment 6 15 1323 1332 O
with 16 20 1333 1337 O
an 21 23 1338 1340 O
MMAE 24 28 1341 1345 B-treatment
- 28 29 1345 1346 I-treatment
containing 29 39 1346 1356 I-treatment
therapy 40 47 1357 1364 I-treatment

